642 related articles for article (PubMed ID: 21427197)
1. Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension.
La Mura V; Reverter JC; Flores-Arroyo A; Raffa S; Reverter E; Seijo S; Abraldes JG; Bosch J; García-Pagán JC
Gut; 2011 Aug; 60(8):1133-8. PubMed ID: 21427197
[TBL] [Abstract][Full Text] [Related]
2. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis.
Ferlitsch M; Reiberger T; Hoke M; Salzl P; Schwengerer B; Ulbrich G; Payer BA; Trauner M; Peck-Radosavljevic M; Ferlitsch A
Hepatology; 2012 Oct; 56(4):1439-47. PubMed ID: 22532296
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of worsening portal hypertension during long-term medical treatment in patients with cirrhosis who had been classified as early good-responders on haemodynamic criteria.
Merkel C; Bolognesi M; Berzigotti A; Amodio P; Cavasin L; Casarotto IM; Zoli M; Gatta A
J Hepatol; 2010 Jan; 52(1):45-53. PubMed ID: 19914730
[TBL] [Abstract][Full Text] [Related]
4. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.
Ripoll C; Groszmann R; Garcia-Tsao G; Grace N; Burroughs A; Planas R; Escorsell A; Garcia-Pagan JC; Makuch R; Patch D; Matloff DS; Bosch J;
Gastroenterology; 2007 Aug; 133(2):481-8. PubMed ID: 17681169
[TBL] [Abstract][Full Text] [Related]
5. Von Willebrand factor antigen for detection of hepatopulmonary syndrome in patients with cirrhosis.
Horvatits T; Drolz A; Roedl K; Herkner H; Ferlitsch A; Perkmann T; Müller C; Trauner M; Schenk P; Fuhrmann V
J Hepatol; 2014 Sep; 61(3):544-9. PubMed ID: 24798623
[TBL] [Abstract][Full Text] [Related]
6. Effect of carvedilol on portal hypertension depends on the degree of endothelial activation and inflammatory changes.
Bruha R; Vitek L; Petrtyl J; Lenicek M; Urbanek P; Zelenka J; Jachymova M; Svestka T; Kalab M; Dousa M; Marecek Z
Scand J Gastroenterol; 2006 Dec; 41(12):1454-63. PubMed ID: 17101577
[TBL] [Abstract][Full Text] [Related]
7. Clinical, laboratory, and hemodynamic parameters in portal hypertensive gastropathy: a study of 254 cirrhotics.
Kumar A; Mishra SR; Sharma P; Sharma BC; Sarin SK
J Clin Gastroenterol; 2010 Apr; 44(4):294-300. PubMed ID: 19730114
[TBL] [Abstract][Full Text] [Related]
8. [Measurement of hepatic venous pressure gradient in liver cirrhosis: relationship with the status of cirrhosis, varices, and ascites in Korea].
Kim MY; Baik SK; Suk KT; Yea CJ; Lee IY; Kim JW; Cha SH; Kim YJ; Um SH; Han KH
Korean J Hepatol; 2008 Jun; 14(2):150-8. PubMed ID: 18617762
[TBL] [Abstract][Full Text] [Related]
9. Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis.
Grønbaek H; Sandahl TD; Mortensen C; Vilstrup H; Møller HJ; Møller S
Aliment Pharmacol Ther; 2012 Jul; 36(2):173-80. PubMed ID: 22591184
[TBL] [Abstract][Full Text] [Related]
10. A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study.
Spahr L; Giostra E; Frossard JL; Morard I; Mentha G; Hadengue A
Am J Gastroenterol; 2007 Jul; 102(7):1397-405. PubMed ID: 17488248
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of plasma soluble P-selectin and von Willebrand factor as indices of platelet activation and endothelial damage/dysfunction in high-risk patients with hypertension: a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial.
Varughese GI; Patel JV; Tomson J; Blann AD; Hughes EA; Lip GY
J Intern Med; 2007 Apr; 261(4):384-91. PubMed ID: 17391113
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of hepatic venous pressure gradient in patients with compensated chronic hepatitis C-related cirrhosis.
Rincón D; Lo Iacono O; Tejedor M; Hernando A; Ripoll C; Catalina MV; Salcedo M; Matilla A; Senosiain M; Clemente G; Molinero LM; Albillos A; Bañares R
Scand J Gastroenterol; 2013 Apr; 48(4):487-95. PubMed ID: 22871085
[TBL] [Abstract][Full Text] [Related]
13. Correlation and comparison of the model for end-stage liver disease, portal pressure, and serum sodium for outcome prediction in patients with liver cirrhosis.
Wang YW; Huo TI; Yang YY; Hou MC; Lee PC; Lin HC; Lee FY; Chi CW; Lee SD
J Clin Gastroenterol; 2007 Aug; 41(7):706-12. PubMed ID: 17667056
[TBL] [Abstract][Full Text] [Related]
14. TIMP-1 in patients with cirrhosis: relation to liver dysfunction, portal hypertension, and hemodynamic changes.
Busk TM; Bendtsen F; Nielsen HJ; Jensen V; Brünner N; Møller S
Scand J Gastroenterol; 2014 Sep; 49(9):1103-10. PubMed ID: 25048331
[TBL] [Abstract][Full Text] [Related]
15. Liver collagen in cirrhosis correlates with portal hypertension and liver dysfunction.
Nielsen K; Clemmesen JO; Vassiliadis E; Vainer B
APMIS; 2014 Dec; 122(12):1213-22. PubMed ID: 25053449
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of hepatic venous pressure gradient for in-hospital mortality of patients with severe acute alcoholic hepatitis.
Rincon D; Lo Iacono O; Ripoll C; Gomez-Camarero J; Salcedo M; Catalina MV; Hernando A; Clemente G; Matilla A; Nuñez O; Bañares R
Aliment Pharmacol Ther; 2007 Apr; 25(7):841-8. PubMed ID: 17373923
[TBL] [Abstract][Full Text] [Related]
17. von Willebrand factor as a novel noninvasive predictor of portal hypertension and esophageal varices in hepatitis B patients with cirrhosis.
Wu H; Yan S; Wang G; Cui S; Zhang C; Zhu Q
Scand J Gastroenterol; 2015; 50(9):1160-9. PubMed ID: 25877661
[TBL] [Abstract][Full Text] [Related]
18. Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity.
Mandorfer M; Schwabl P; Paternostro R; Pomej K; Bauer D; Thaler J; Ay C; Quehenberger P; Fritzer-Szekeres M; Peck-Radosavljevic M; Trauner M; Reiberger T; Ferlitsch A;
Aliment Pharmacol Ther; 2018 Apr; 47(7):980-988. PubMed ID: 29377193
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension.
La Mura V; Abraldes JG; Raffa S; Retto O; Berzigotti A; García-Pagán JC; Bosch J
J Hepatol; 2009 Aug; 51(2):279-87. PubMed ID: 19501930
[TBL] [Abstract][Full Text] [Related]
20. Endotoxin and tumor necrosis factor-receptor levels in portal and hepatic vein of patients with alcoholic liver cirrhosis receiving elective transjugular intrahepatic portosystemic shunt.
Trebicka J; Krag A; Gansweid S; Appenrodt B; Schiedermaier P; Sauerbruch T; Spengler U
Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1218-25. PubMed ID: 21971377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
